Managing Serious Infections in Patients with Malignancy

Bacterial Infections in Patients with Cancer: New Challenges, New Opportunities- The management of serious bacterial infections in patients with malignancy is becoming particularly challenging in the light of increasing antimicrobial resistance among key pathogens and limited therapeutic options. Oncologists must take a proactive role in ensuring early identification of infection in high-risk patients with cancer followed by urgent treatment. This educational activity is designed to enhance the awareness and knowledge of the latest advancements and clinical findings, as well as offer a broad understanding of current and emerging therapeutic options when treating serious bacterial infections.
This program is divided into three learning blocks that focus on key pathogens: (1) Gram-positive bacteria (e.g., S. aureus, MRSA, enterococci), (2) Gram-negative bacteria (e.g., ESBL- and carbapenemase-producing Enterobacteriaceae, P. aeruginosa), and (3) C. difficile. Current trends in the evolving epidemiology of infection in patients with cancer are discussed. Management approaches will focus on effective treatment strategies for infections caused by MDR bacteria.
Discuss the evolving epidemiology of Gram-negative and Gram-positive bacterial infections in patients with cancer.
Assess patient risk and local epidemiological factors when selecting antimicrobial therapy for bacterial infection in patients with neutropenic fever.
Implement evidence-based guideline approaches in the management of C. difficile infection in patients with cancer.

2.0 Free CEUs for Pharmacists

Expires  6/13/15

This activity is jointly sponsored by 
Center for Independent Healthcare Education and Vemco MedEd.
This activity is supported by an educational grant from Cubist Pharmaceuticals.